001     143228
005     20240229112545.0
024 7 _ |a 10.1093/ajcn/nqy223
|2 doi
024 7 _ |a pmid:30668630
|2 pmid
024 7 _ |a 0002-9165
|2 ISSN
024 7 _ |a 0095-9871
|2 ISSN
024 7 _ |a 1938-3207
|2 ISSN
024 7 _ |a 1938-3215
|2 ISSN
024 7 _ |a altmetric:54227658
|2 altmetric
037 _ _ |a DKFZ-2019-00827
041 _ _ |a eng
082 _ _ |a 570
100 1 _ |a Jung, Audrey Y
|0 P:(DE-HGF)0
|b 0
|e First author
245 _ _ |a Antioxidant supplementation and breast cancer prognosis in postmenopausal women undergoing chemotherapy and radiation therapy.
260 _ _ |a Oxford
|c 2019
|b Oxford University Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1554212834_30312
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a There is a paucity of information on the prevalence of dietary supplement use in breast cancer survivors. Only a few studies have examined the impact of dietary supplements, particularly antioxidants, on breast cancer prognosis and the results are inconclusive.We examined pre- and postdiagnosis use of supplements in postmenopausal breast cancer survivors in Germany and investigated associations between postdiagnosis use of antioxidants and other supplements, and prognosis (total and breast cancer mortality, and recurrence-free survival) both overall and in women who received chemotherapy and radiation therapy.Data from 2223 postmenopausal women diagnosed with nonmetastatic breast cancer from the population-based Mamma Carcinoma Risk Factor Investigation (MARIE) study were used. Women were interviewed at recruitment in 2002-2005 and again in 2009 and followed-up until 30 June 2015. Multivariate Cox regression analysis was used to estimate HRs and corresponding 95% CIs.Pre- and postdiagnosis supplement use was reported by 36% and 45% of the women, respectively. There were 240 deaths (134 from breast cancer) and 200 breast cancer recurrences after a median follow-up time of 6.0 y after the 2009 re-interview. After adjusting for relevant confounders, concurrent antioxidant use with chemotherapy or radiation therapy among 1940 women was associated with increased risk of total mortality (HR: 1.64; 95% CI: 1.01, 2.66) and worsened recurrence-free survival (HR: 1.84; 95% CI: 1.26, 2.68). Overall postdiagnosis supplement use was not associated with breast cancer prognosis.Antioxidant use during chemotherapy or radiation therapy was associated with worsened breast cancer prognosis in postmenopausal women. There was no overall association between postdiagnosis supplement use and breast cancer prognosis. Results from our study align with the current recommendation to possibly avoid the use of antioxidants during chemotherapy or radiation therapy.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Cai, Xinting
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Thoene, Kathrin
|b 2
700 1 _ |a Obi, Nadia
|b 3
700 1 _ |a Jaskulski, Stefanie
|0 P:(DE-He78)e16e2a17f7dd2e7f7e917c0382f19b2d
|b 4
|u dkfz
700 1 _ |a Behrens, Sabine
|0 P:(DE-He78)6b04712f3afe72044d496a25505cb1ea
|b 5
|u dkfz
700 1 _ |a Flesch-Janys, Dieter
|b 6
700 1 _ |a Chang-Claude, Jenny
|0 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
|b 7
|e Last author
|u dkfz
773 _ _ |a 10.1093/ajcn/nqy223
|g Vol. 109, no. 1, p. 69 - 78
|0 PERI:(DE-600)1496439-9
|n 1
|p 69 - 78
|t The American journal of clinical nutrition
|v 109
|y 2019
|x 1938-3207
909 C O |o oai:inrepo02.dkfz.de:143228
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)e16e2a17f7dd2e7f7e917c0382f19b2d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)6b04712f3afe72044d496a25505cb1ea
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2019
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b AM J CLIN NUTR : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b AM J CLIN NUTR : 2017
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l Epidemiologie von Krebserkrankungen
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21